UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C., 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
March 22, 2010
Date of Report (Date of earliest event reported)
CELLCYTE GENETICS CORPORATION
(Exact name of registrant as specified in its charter)
Nevada | 000-52238 | 86-1127046 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
14205 SE 36th St. Suite 100, Bellevue Washington |
| 98006 |
(Address of principal executive offices) |
| (Zip Code) |
(425) 519-3659
Registrant's telephone number, including area code
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Section 8 – Other Events
Item 8.01 Other Events
In January 2008, three stockholder lawsuits were filed against us in the United States federal court for the Western District of Washington: Armbruster v. Cellcyte Genetics Corporation, et. al, No. C08-0047, Tolerico v. Cellcyte Genetics Corporation, et. al., No. C08-0163 and Pruitt v. Cellcyte Genetics Corporation, et. al., No. C08-0178. The lawsuits were consolidated into one action.
On March 22, 2010, the consolidated lawsuit was dismissed, thereby dismissing all lawsuits referenced above. Cellcyte Genetics did not pay any amount in consideration of the dismissal, and all parties are responsible for their own costs. This dismissal also applies to both Company co-founders, who were named as co-defendants in the lawsuit.
Cellcyte Genetics has now resolved all lawsuits and arbitrations filed against it by employees, shareholders and the Securities and Exchange Commission. No corporate funds were paid to any of the plaintiffs or claimants in connection with these resolutions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CELLCYTE GENETICS CORPORATION |
Date: March 24, 2010. | _______________________________________ |
![[f8ksecsettlementconsolida002.gif]](f8ksecsettlementconsolida002.gif){kind=small}